BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31476594)

  • 1. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.
    Issac MSM; Yousef E; Tahir MR; Gaboury LA
    Neoplasia; 2019 Oct; 21(10):1015-1035. PubMed ID: 31476594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.
    Yousef EM; Furrer D; Laperriere DL; Tahir MR; Mader S; Diorio C; Gaboury LA
    Mod Pathol; 2017 May; 30(5):682-697. PubMed ID: 28084344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers.
    Sadeghian D; Saffar H; Mahdavi Sharif P; Soleimani V; Jahanbin B
    Diagn Pathol; 2022 Feb; 17(1):24. PubMed ID: 35125121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression Profile and Prognostic Values of Mini-Chromosome Maintenance Families (MCMs) in Breast Cancer.
    Cheng L; Tan Z; Huang Z; Pan Y; Zhang W; Wang J
    Med Sci Monit; 2020 Aug; 26():e923673. PubMed ID: 32830194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.
    Montes de Oca R; Gurard-Levin ZA; Berger F; Rehman H; Martel E; Corpet A; de Koning L; Vassias I; Wilson LO; Meseure D; Reyal F; Savignoni A; Asselain B; Sastre-Garau X; Almouzni G
    Mol Oncol; 2015 Mar; 9(3):657-74. PubMed ID: 25497280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
    Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
    Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
    Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
    Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
    BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Gerstenhauer M; Brockhoff G; Ortmann O
    Breast Cancer Res Treat; 2015 Oct; 153(3):647-58. PubMed ID: 26369534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Diagnostic and Prognostic Values of Minichromosome Maintenance Gene Expression in Patients with Hepatocellular Carcinoma.
    Liao X; Liu X; Yang C; Wang X; Yu T; Han C; Huang K; Zhu G; Su H; Qin W; Huang R; Yu L; Deng J; Zeng X; Ye X; Peng T
    J Cancer; 2018; 9(13):2357-2373. PubMed ID: 30026832
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes.
    Liang Q; Ma D; Gao RF; Yu KD
    Sci Rep; 2020 May; 10(1):7648. PubMed ID: 32376868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.